What do we know about the secretion and degradation of incretin hormones?

The incretin hormones, glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) are secreted from endocrine cells located in the intestinal mucosa, and act to enhance meal-induced insulin secretion. GIP and GLP-1 concentrations in the plasma rise rapidly after food ingestion, and the presence of unabsorbed nutrients in the intestinal lumen is a strong stimulus for their secretion. Nutrients can stimulate release of both hormones by direct contact with the K-cell (GIP) and L-cell (GLP-1), and this may be the most important signal. However, nutrients also stimulate GLP-1 and GIP secretion indirectly via other mechanisms. Incretin hormone secretion can be modulated neurally, with cholinergic muscarinic, beta-adrenergic and peptidergic (gastrin-releasing peptide, GRP) fibres generally having positive effects, while secretion is restrained by alpha-adrenergic and somatostatinergic fibres. Hormonal factors may also influence incretin hormone secretion. Somatostatin exerts a local inhibitory effect on the activity of both K- and L-cells via a paracrine mechanism, while, in rodents at least, GIP from the proximal intestine has a stimulatory effect on GLP-1 secretion, possibly mediated via a neural loop involving GRP. Once they have been released, both GLP-1 and GIP are subject to rapid degradation. The ubiquitous enzyme, dipeptidyl peptidase IV (DPP IV) cleaves N-terminally, removing a dipeptide and thereby inactivating both peptides, because the N-terminus is crucial for receptor binding. Subsequently, the peptides may be degraded by other enzymes and extracted in an organ-specific manner. The intact peptides are inactivated during passage across the hepatic bed and further metabolised by the peripheral tissues, while the kidney is important for the final elimination of the metabolites.

[1]  K. Moley,et al.  Studies with GIP/Ins cells indicate secretion by gut K cells is KATP channel independent. , 2003, American journal of physiology. Endocrinology and metabolism.

[2]  J. Holst,et al.  Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. , 1996, Scandinavian journal of gastroenterology.

[3]  P. Brubaker,et al.  Muscarinic receptors control glucagon-like peptide 1 secretion by human endocrine L cells. , 2003, Endocrinology.

[4]  H. Mekhjian,et al.  Selective release of gastric inhibitory polypeptide by intraduodenal amino acid perfusion in man. , 1978, Gastroenterology.

[5]  M. Namba,et al.  Decrease in blood glucose and release of gut glucagon-like immunoreactive materials by bombesin infusion in the dog. , 1980, Endocrinologia japonica.

[6]  B. Gallwitz,et al.  Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. , 1993, European journal of biochemistry.

[7]  A. Buchan,et al.  Immunocytochemical evidence for a paracrine interaction between GIP and GLP-1-producing cells in canine small intestine , 1999, Cell and Tissue Research.

[8]  B. Göke,et al.  Gastric emptying and release of incretin hormones after glucose ingestion in humans. , 1996, The Journal of clinical investigation.

[9]  J. Dupré,et al.  Effects of Ingestion of Triglyceride or Galactose on Secretion of Gastric Inhibitory Polypeptide and on Responses to Intravenous Glucose in Normal and Diabetic Subjects , 1978, Diabetes.

[10]  J. Holst,et al.  Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7–36 amide]) in patients with NIDDM , 1996, Diabetologia.

[11]  J. Holst,et al.  Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs. , 2001, Diabetes.

[12]  Bo Ahrén,et al.  Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. , 2002, Diabetes care.

[13]  J. Polak,et al.  Electronimmunocytochemical evidence for the K cell localization of gastric inhibitory polypeptide (GIP) im man , 1978, Histochemistry.

[14]  M. Wolfe,et al.  Release of gastric inhibitory peptide following a peptone meal in the dog. , 1982, Gastroenterology.

[15]  J. Holst,et al.  Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. , 2000, The Journal of clinical endocrinology and metabolism.

[16]  H. Vermeer,et al.  Glucagon‐like peptide‐1 cells in the gastrointestinal tract and pancreas of rat, pig and man , 1992, European journal of clinical investigation.

[17]  J. Holst,et al.  Glucagon-Like Peptide-1-(7-36)Amide Is Transformed to Glucagon-Like Peptide-1-(9-36)Amide by Dipeptidyl Peptidase IV in the Capillaries Supplying the L Cells of the Porcine Intestine1. , 1999, Endocrinology.

[18]  H. Berthoud,et al.  Lack of Gastric Inhibitory Polypepetide (GIP) response to vagal stimulation in the rat , 1982, Peptides.

[19]  R. Pederson,et al.  Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. , 1995, Endocrinology.

[20]  J. Brown,et al.  Gastric inhibitory polypeptide and glucagon-like peptide-1(7-36) amide exert similar effects on somatostatin secretion but opposite effects on gastrin secretion from the rat stomach. , 1994, Canadian journal of physiology and pharmacology.

[21]  J. Holst,et al.  Release of glucagon-like peptide 1 (GLP-1 [7-36 amide]), gastric inhibitory polypeptide (GIP) and insulin in response to oral glucose after upper and lower intestinal resections. , 1996, Zeitschrift fur Gastroenterologie.

[22]  Bo Ahrén,et al.  0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(5):2078–2084 Printed in U.S.A. Copyright © 2004 by The Endocrine Society doi: 10.1210/jc.2003-031907 Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels , 2022 .

[23]  J. Holst,et al.  All products of proglucagon are elevated in plasma from uremic patients. , 1992, The Journal of clinical endocrinology and metabolism.

[24]  F. Carone,et al.  Renal tubular processing of small peptide hormones. , 1982, The Journal of laboratory and clinical medicine.

[25]  O. Flaten,et al.  Beta-adrenergic stimulation and blockade of the release of gastric inhibitory polypeptide and insulin in man. , 1982, Scandinavian journal of gastroenterology.

[26]  J. Holst,et al.  Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. , 1986, Endocrinology.

[27]  B. Göke,et al.  Endoproteolysis of Glucagon-like Peptide (GLP)-1(7–36) amide by Ectopeptidases in RINm5F Cells , 1997, Peptides.

[28]  I. Valverde,et al.  Renal catabolism of truncated glucagon-like peptide 1. , 1993, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[29]  R. Bruzzone,et al.  Effect of bombesin on plasma insulin, pancreatic glucagon, and gut glucagon in man. , 1983, The Journal of clinical endocrinology and metabolism.

[30]  J. Holst,et al.  Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. , 1996, The American journal of physiology.

[31]  W. Meyers,et al.  The hepatic extraction of gastric inhibitory polypeptide and insulin. , 1984, Endocrinology.

[32]  Rolf Mentlein,et al.  Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides , 1999, Regulatory Peptides.

[33]  J. Holst,et al.  Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. , 2001, The Journal of clinical endocrinology and metabolism.

[34]  A. Buchan,et al.  Glucagon-like-peptide-1 secretion from canine L-cells is increased by glucose-dependent-insulinotropic peptide but unaffected by glucose. , 1998, Endocrinology.

[35]  P. Brubaker Control of glucagon-like immunoreactive peptide secretion from fetal rat intestinal cultures. , 1988, Endocrinology.

[36]  J. Cuber,et al.  Stimulatory effect of beta-adrenergic agonists on ileal L cell secretion and modulation by alpha-adrenergic activation. , 1999, The Journal of endocrinology.

[37]  B. Göke,et al.  Regulation of glucagon-like peptide-1 secretion from rat ileum by neurotransmitters and peptides. , 1995, The Journal of endocrinology.

[38]  J. Brown,et al.  Gastric Inhibitory Polypeptide: Its Physiologic Release and Insulinotropic Action in the Dog , 1975, Diabetes.

[39]  D J Drucker,et al.  Printed in U.S.A. Copyright © 1998 by The Endocrine Society Regulation of Glucagon-Like Peptide-1 Synthesis and , 2022 .

[40]  Wang Wc,et al.  Inhibition of somatostatin on glucose-induced release of gastric inhibitory polypeptide in rats. , 1987 .

[41]  S. Werlin,et al.  Effects of cholecystokinin-receptor blockade on pancreatic and biliary function in healthy volunteers. , 1991, Gastroenterology.

[42]  G. Greenberg,et al.  Neural Modulation of Glucose‐Dependent Insulinotropic Peptide (GIP) and Insulin Secretion in Conscious Dogs , 1994, Pancreas.

[43]  A. Katz,et al.  Glucagon metabolism in the rat. , 1978, The Journal of clinical investigation.

[44]  T. O'dorisio,et al.  Absence of hepatic extraction of gastric inhibitory polypeptide in conscious dogs , 1987, Digestive Diseases and Sciences.

[45]  J. Holst,et al.  Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients , 1993, Diabetologia.

[46]  J. Holst,et al.  Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypoglycemia after total gastrectomy , 1991, Digestive Diseases and Sciences.

[47]  G. Greenberg,et al.  Truncated and full-length glucagon-like peptide-1 (GLP-1) differentially stimulate intestinal somatostatin release , 1997, Endocrine.

[48]  K. Sirinek,et al.  Chronic renal failure: effect of hemodialysis on gastrointestinal hormones. , 1984, American journal of surgery.

[49]  J. Elovson Biogenesis of plasma membrane glycoproteins. Purification and properties of two rat liver plasma membrane glycoproteins. , 1980, The Journal of biological chemistry.

[50]  J. Holst,et al.  Glucagon-like peptide-1 secretion is influenced by perfusate glucose concentration and by a feedback mechanism involving somatostatin in isolated perfused porcine ileum , 2004, Regulatory Peptides.

[51]  E. Mazzaferri,et al.  Gastric inhibitory polypeptide (GIP) stimulated by fat ingestion in man. , 1975, The Journal of clinical endocrinology and metabolism.

[52]  G. Greenberg,et al.  Somatostatin-28 regulates GLP-1 secretion via somatostatin receptor subtype 5 in rat intestinal cultures. , 2002, American journal of physiology. Endocrinology and metabolism.

[53]  F. Reimann,et al.  Glucose-sensing in glucagon-like peptide-1-secreting cells. , 2002, Diabetes.

[54]  J. Holst,et al.  Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7–36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats , 1999, Diabetologia.

[55]  J. Holst,et al.  Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. , 1993, The Journal of clinical investigation.

[56]  G. Greenberg,et al.  The role of vagal integrity in gastrin releasing peptide stimulated gastroenteropancreatic hormone release and gastric acid secretion , 1985, Regulatory Peptides.

[57]  J. Chayvialle,et al.  Regulation of glucagon-like peptide-1-(7-36) amide secretion by intestinal neurotransmitters and hormones in the isolated vascularly perfused rat colon. , 1994, Endocrinology.

[58]  P. Layer,et al.  Ileal release of glucagon-like peptide-1 (GLP-1) , 1995, Digestive Diseases and Sciences.

[59]  J. Holst,et al.  Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects , 1995, Diabetes.

[60]  Tanya Hansotia,et al.  Muscarinic receptors control postprandial release of glucagon-like peptide-1: in vivo and in vitro studies in rats. , 2002, Endocrinology.

[61]  J. Holst,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2000 by The Endocrine Society Antidiabetogenic Action of Cholecystokinin-8 in Type 2 Diabetes* , 2022 .

[62]  L. B. Knudsen,et al.  Structure-activity studies of glucagon-like peptide-1. , 1994, The Journal of biological chemistry.

[63]  J. Holst,et al.  GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine , 2003, Regulatory Peptides.

[64]  M. Nauck,et al.  Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. , 1993, The Journal of clinical endocrinology and metabolism.

[65]  D. Marguet,et al.  Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[66]  E. Mazzaferri,et al.  Renal effects on serum gastric inhibitory polypeptide (GIP). , 1977, Metabolism: clinical and experimental.

[67]  J. Chayvialle,et al.  Regulation of glucagon-like peptide-1-(7-36) amide, peptide YY, and neurotensin secretion by neurotransmitters and gut hormones in the isolated vascularly perfused rat ileum. , 1995, Endocrinology.

[68]  John R. Christiansen,et al.  Glucagon-like peptide-1 7-36 amide and peptide YY from the L-cell of the ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man. , 1994, Scandinavian journal of gastroenterology.

[69]  B. Göke,et al.  Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. , 1995, Digestion.

[70]  J. Holst,et al.  Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. , 1995, The Journal of clinical endocrinology and metabolism.

[71]  M. Nauck Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective , 1998, Acta Diabetologica.

[72]  B. Göke,et al.  Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7–36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides , 1995, Regulatory Peptides.

[73]  P. Brubaker,et al.  Gastrin-releasing peptide is a novel mediator of proximal nutrient-induced proglucagon-derived peptide secretion from the distal gut. , 1996, Endocrinology.

[74]  J. Brown,et al.  Release of gastric inhibitory polypeptide from cultured canine endocrine cells. , 1994, The American journal of physiology.

[75]  F. Reimann,et al.  A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. , 2003, Diabetes.

[76]  V. Mutt,et al.  Amino acid sequence and heterogeneity of gastric inhibitory polypeptide (GIP) , 1981, FEBS letters.

[77]  J. Brown,et al.  Gastric inhibitory polypeptide (GIP) stimulation by oral glucose in man. , 1974, The Journal of clinical endocrinology and metabolism.

[78]  J. Holst,et al.  The cephalic insulin response to meal ingestion in humans is dependent on both cholinergic and noncholinergic mechanisms and is important for postprandial glycemia. , 2001, Diabetes.

[79]  D. Buckley Analysis of the degradation of insulinotropin [GLP-1(7–37)] in human plasma and production of degradation resistant analogs , 1992, Regulatory Peptides.

[80]  J. Holst,et al.  Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum. , 2000, American journal of physiology. Endocrinology and metabolism.

[81]  P. Brubaker,et al.  Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop. , 1993, Endocrinology.

[82]  J. Holst,et al.  Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. , 1998, Diabetes.

[83]  J. Holst,et al.  Rapid oscillations in plasma glucagon-like peptide-1 (GLP-1) in humans: cholinergic control of GLP-1 secretion via muscarinic receptors. , 1997, The Journal of clinical endocrinology and metabolism.

[84]  P. Brubaker,et al.  Printed in U.S.A. Copyright © 1999 by The Endocrine Society Role of the Vagus Nerve in Mediating Proximal Nutrient- Induced Glucagon-Like Peptide-1 Secretion* , 2022 .

[85]  M. Wolfe,et al.  Regulation of glucose-dependent insulinotropic polypeptide release by protein in the rat. , 2000, American journal of physiology. Gastrointestinal and liver physiology.

[86]  J. Holst,et al.  Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. , 2003, The Journal of clinical endocrinology and metabolism.

[87]  J. Holst,et al.  Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. , 2004, Diabetes.

[88]  M. Imamura,et al.  Role of vagus nerve in secretion of gastric inhibitory polypeptide in dogs. , 1985, The Tohoku journal of experimental medicine.

[89]  J. Holst,et al.  Physiological augmentation of amino acid-induced insulin secretion by GIP and GLP-I but not by CCK-8. , 1995, The American journal of physiology.

[90]  I. Cleator,et al.  Release of immunoreactive gastric inhibitory polypeptide (IR-GIP) by oral ingestion of food substances. , 1975, American journal of surgery.

[91]  C. Beglinger,et al.  Effect of a cholecystokinin antagonist on meal-stimulated insulin and pancreatic polypeptide release in humans. , 1991, The Journal of clinical endocrinology and metabolism.

[92]  J. Holst,et al.  Postprandial GLP-1, Norepinephrine, and Reactive Hypoglycemia in Dumping Syndrome , 2001, Digestive Diseases and Sciences.

[93]  J. Holst,et al.  The effects of duodenal peptides on glucagon-like peptide-1 secretion from the ileum A duodeno–ileal loop? , 2002, Regulatory Peptides.

[94]  V. Marks,et al.  Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. , 1993, The Journal of endocrinology.

[95]  J. Holst,et al.  Postprandial release of glucagon-like peptide-1, pancreatic glucagon, and insulin after esophageal resection. , 1993, Digestion.

[96]  W. Creutzfeldt,et al.  Reversal of impaired GIP and insulin secretion in patients with pancreatogenic steatorrhea following enzyme substitution , 1980, Diabetologia.

[97]  T. Hughes,et al.  Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. , 2002, The Journal of endocrinology.

[98]  P. Brubaker,et al.  Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2. , 2003, Canadian journal of physiology and pharmacology.

[99]  G. Greeley,et al.  Terbutaline, A β2-Adrenoreceptor agonist, inhibits gastric acid secretion and stimulates release of peptide YY and gastric inhibitory polypeptide in dogs , 1990, Digestive Diseases and Sciences.

[100]  T. Dakka,et al.  Peptide YY, Glucagon-Like Peptide-1, and Neurotensin Responses to Luminal Factors in the Isolated Vascularly Perfused Rat Ileum. , 1998, Endocrinology.

[101]  P. Giacomoni,et al.  Adrenergic modulation of gastric inhibitory polypeptide secretion in man , 1980, Regulatory Peptides.

[102]  R. Jorde,et al.  Removal of IR-GIP by the kidneys in man, and the effect of acute nephrectomy on plasma GIP in rats. , 1981, Scandinavian journal of gastroenterology.

[103]  S. Bloom,et al.  A radioimmunoassay of gastric inhibitory polypeptide in human plasma. , 1980, The Journal of endocrinology.

[104]  J. Holst,et al.  Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. , 1992, The New England journal of medicine.

[105]  T. Adrian,et al.  Bombesin receptor subtype mediation of gastroenteropancreatic hormone secretion in rats , 1994, Peptides.